Integrative genomic analyses of the histamine H1 receptor and its role in cancer prediction

Wang,Minghai; Wei,Xiaolong; Shi,Lianghui; Chen,Bin; Zhao,Guohai; Yang,Haiwei

doi:10.3892/ijmm.2014.1649

Integrative genomic analyses of the histamine H1 receptor and its role in cancer prediction

Authors:
- Minghai Wang
- Xiaolong Wei
- Lianghui Shi
- Bin Chen
- Guohai Zhao
- Haiwei Yang
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Yijishan Hospital of Wannan Medical College, Wuhu 241001, P.R. China, Department of Pathology, Cancer Hospital of Shantou University Medical College, Shantou 515041, P.R. China, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China
Published online on: February 10, 2014 https://doi.org/10.3892/ijmm.2014.1649
Pages: 1019-1026

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The human histamine receptor H1 (HRH1) gene is located on chromosome 3p25 and encodes for a 487 amino acid G protein-coupled receptor (GPCR) with a long third intracellular loop (IL3). The HRH1 predominantly couples to Gαq/11 proteins, leading to the activation of phospholipase C (PLC) and subsequent release of the second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG) followed by the activation of PKC and the release of [Ca2+]i. In the present study, we identified HRH1 genes from 14 vertebrate genomes and found that HRH1 exists in all types of vertebrates including fish, amphibians, birds and mammals. We identified 88 SNPs including 4 available alleles disrupting an existing exonic splicing enhancer and 84 SNPs causing missense mutation, which may impact the effect of histamine on the HRH1 protein. We found that the human HRH1 gene was expressed in many tissues or organs, and predominant expression of HRH1 was shown in the bone marrow, whole blood, lymph node, thymus, brain, cerebellum, retina, spinal cord, heart, smooth muscle, skeletal muscle, small intestine, colon, adipocytes, kidney, liver, lung, pancreas, thyroid salivary gland, skin, ovary, uterus, placenta, prostate and testis. When searched in the PrognoScan database, human HRH1 was also found to be expressed in bladder cancer, blood cancer, brain cancer, breast cancer, colorectal cancer, eye cancer, head and neck cancer, lung cancer, ovarian cancer, skin cancer and soft tissue cancer tissues. The relationship between the expression of HRH1 and prognosis was found to vary in different types of cancers, even in the same cancer from different databases. This implies that the function of HRH1 in these tumors may be multidimensional. GR, STAT5A and c-Myb regulatory transcription factor binding sites were identified in the HRH1 gene upstream (promoter) region, which may be involved in the effect of HRH1 in tumors.

View Figures

View References

1	Seifert R, Strasser A, Schneider EH, Neumann D, Dove S and Buschauer A: Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol Sci. 34:33–58. 2013. View Article : Google Scholar : PubMed/NCBI
2	Yoshizawa M, Tashiro M, Fukudo S, et al: Increased brain histamine H1 receptor binding in patients with anorexia nervosa. Biol Psychiatry. 65:329–335. 2009. View Article : Google Scholar : PubMed/NCBI
3	Booth RG, Fang L, Wilczynski A, et al: Molecular determinants of ligand-directed signaling for the histamine H1 receptor. Inflamm Res. 57(Suppl 1): S43–S44. 2008. View Article : Google Scholar : PubMed/NCBI
4	Swan C, Richards SA, Duroudier NP, Sayers I and Hall IP: Alternative promoter use and splice variation in the human histamine H1 receptor gene. Am J Respir Cell Mol Biol. 35:118–226. 2006. View Article : Google Scholar : PubMed/NCBI
5	Oda T, Morikawa N, Saito Y, Masuho Y and Matsumoto S: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem. 275:36781–36788. 2000. View Article : Google Scholar : PubMed/NCBI
6	Breunig E, Michel K, Zeller F, Seidl S, Weyhern CW and Schemann M: Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol. 583:731–742. 2007. View Article : Google Scholar : PubMed/NCBI
7	Brew OB and Sullivan MH: Localisation of mRNAs for diamine oxidase and histamine receptors H1 and H2, at the feto-maternal interface of human pregnancy. Inflamm Res. 50:449–452. 2001. View Article : Google Scholar : PubMed/NCBI
8	Arisawa T, Tahara T, Ozaki K, et al: Association between common genetic variant of HRH2 and gastric cancer risk. Int J Oncol. 41:497–503. 2012.
9	Lefranc F, Yeaton P, Brotchi J and Kiss R: Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma. Int J Oncol. 28:1021–1030. 2006.PubMed/NCBI
10	Davio C, Baldi A, Mladovan A, Cricco G, Fitzsimons C and Bergoc RR: Expression of histamine receptors in different cell lines derived from mammary gland and human breast carcinomas. Inflamm Res. 44(Suppl 1): S70–S71. 1995. View Article : Google Scholar : PubMed/NCBI
11	Jiang CG, Liu FR, Yu M, Li JB and Xu HM: Cimetidine induces apoptosis in gastric cancer cells in vitro and inhibits tumor growth in vivo. Oncol Rep. 23:693–700. 2010.PubMed/NCBI
12	Fukuda M, Tanaka S, Suzuki S, Kusama K, Kaneko T and Sakashita H: Cimetidine induces apoptosis of human salivary gland tumor cells. Oncol Rep. 17:673–678. 2007.PubMed/NCBI
13	Yang L, Luo Y and Wei J: Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. Oncol Rep. 24:571–577. 2010. View Article : Google Scholar : PubMed/NCBI
14	Yang L, Luo Y, Wei J and He S: Integrative genomic analyses on IL28RA, the common receptor of interferon-λ1, -λ2 and -λ3. Int J Mol Med. 25:807–812. 2010.PubMed/NCBI
15	Yang L, Wei J and He S: Integrative genomic analyses on interferon-λs and their roles in cancer prediction. Int J Mol Med. 25:299–304. 2010.
16	Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F and Higgins DG: The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 15:4876–4882. 1997. View Article : Google Scholar : PubMed/NCBI
17	Guindon S, Lethiec F, Duroux P and Gascuel O: PHYML Online - a web server for fast maximum likelihood-based phylogenetic inference. Nucleic Acids Res. 33:W557–W559. 2005. View Article : Google Scholar : PubMed/NCBI
18	Kumar S, Tamura K and Nei M: MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform. 5:150–163. 2004. View Article : Google Scholar : PubMed/NCBI
19	Yang Z: PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci. 13:555–556. 1997.PubMed/NCBI
20	Yang Z, Nielsen R, Goldman N and Pedersen AM: Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics. 155:431–449. 2000.PubMed/NCBI
21	Yu H, Yuan J, Xiao C and Qin Y: Integrative genomic analyses of recepteur d’origine nantais and its prognostic value in cancer. Int J Mol Med. 31:1248–1254. 2013.
22	Katoh Y and Katoh M: Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFβ-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol. 35:187–192. 2009.
23	Katoh M and Katoh M: Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling. Int J Mol Med. 24:247–251. 2009.
24	Katoh M and Katoh M: Transcriptional mechanisms of WNT5A based on NF-κB, Hedgehog, TGFβ, and Notch signaling cascades. Int J Mol Med. 23:763–769. 2009.
25	Katoh M and Katoh M: Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1α, POU/OCT, and NF-κB. Int J Oncol. 34:1737–1742. 2009. View Article : Google Scholar : PubMed/NCBI
26	Chalifa-Caspi V, Yanai I, Ophir R, et al: GeneAnnot: comprehensive two-way linking between oligonucleotide array probesets and GeneCards genes. Bioinformatics. 20:1457–1458. 2004. View Article : Google Scholar : PubMed/NCBI
27	Parkinson H, Sarkans U, Shojatalab M, et al: ArrayExpress - a public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 33:D553–D555. 2005. View Article : Google Scholar : PubMed/NCBI
28	Kolker E, Higdon R, Morgan P, et al: SPIRE: Systematic protein investigative research environment. J Proteomics. 75:122–126. 2011. View Article : Google Scholar : PubMed/NCBI
29	Kolker E, Higdon R, Haynes W, et al: MOPED: Model Organism Protein Expression Database. Nucleic Acids Res. 40:D1093–D1099. 2012. View Article : Google Scholar : PubMed/NCBI
30	Mizuno H, Kitada K, Nakai K and Sarai A: PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
31	Xu TR, Yang Y, Ward R, Gao L and Liu Y: Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cell Signal. 25:2413–2423. 2013. View Article : Google Scholar
32	Medina VA and Rivera ES: Histamine receptors and cancer pharmacology. Br J Pharmacol. 61:755–767. 2010. View Article : Google Scholar
33	Blaya B, Nicolau-Galmés F, Jangi SM, et al: Histamine and histamine receptor antagonists in cancer biology. Inflamm Allergy Drug Targets. 9:146–157. 2010. View Article : Google Scholar : PubMed/NCBI
34	Schlossmacher G, Stevens A and White A: Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol. 211:17–25. 2011. View Article : Google Scholar : PubMed/NCBI
35	Feng Y, Bai X, Yang Q, Wu H and Wang D: Downregulation of 15-lipoxygenase 2 by glucocorticoid receptor in prostate cancer cells. Int J Oncol. 36:1541–1549. 2010.PubMed/NCBI
36	Jang JH, Woo SM, Um HJ, et al: RU486, a glucocorticoid receptor antagonist, induces apoptosis in U937 human lymphoma cells through reduction in mitochondrial membrane potential and activation of p38 MAPK. Oncol Rep. 30:506–512. 2013.
37	Koptyra M, Gupta S, Talati P and Nevalainen MT: Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell Biol. 43:1417–1421. 2011. View Article : Google Scholar : PubMed/NCBI
38	Hou L, Xu B, Mohankumar KM, Goffin V, Perry JK, Lobie PE and Liu DX: The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells. Int J Oncol. 41:2285–2295. 2012.PubMed/NCBI
39	Haeri M, Li Y, Li Y, Li Q, Spaner DE and Ben-David Y: Insertional activation of myb by F-MuLV in SCID mice induces myeloid leukemia. Int J Oncol. 43:169–176. 2013.PubMed/NCBI
40	Zhang J, Luo N, Luo Y, Peng Z, Zhang T and Li S: microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol. 40:747–756. 2012.PubMed/NCBI
41	Kim WJ, Kim EJ, Kim SK, et al: Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 9:32010. View Article : Google Scholar : PubMed/NCBI
42	Lee JS, Leem SH, Lee SY, et al: Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 28:2660–2667. 2010. View Article : Google Scholar : PubMed/NCBI
43	Hummel M, Bentink S, Berger H, et al: Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 354:2419–2430. 2006.PubMed/NCBI
44	Zhan F, Huang Y, Colla S, et al: The molecular classification of multiple myeloma. Blood. 108:2020–2028. 2006. View Article : Google Scholar : PubMed/NCBI
45	Phillips HS, Kharbanda S, Chen R, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
46	Bos PD, Zhang XH, Nadal C, et al: Genes that mediate breast cancer metastasis to the brain. Nature. 459:1005–1009. 2009. View Article : Google Scholar : PubMed/NCBI
47	Loi S, Haibe-Kains B, Majjaj S, et al: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 107:10208–10213. 2010. View Article : Google Scholar : PubMed/NCBI
48	Chanrion M, Negre V, Fontaine H, et al: A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res. 14:1744–1752. 2008. View Article : Google Scholar : PubMed/NCBI
49	Pawitan Y, Bjöhle J, Amler L, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7:R953–R964. 2005. View Article : Google Scholar : PubMed/NCBI
50	Miller LD, Smeds J, George J, et al: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 102:13550–13555. 2005. View Article : Google Scholar : PubMed/NCBI
51	Smith JJ, Deane NG, Wu F, et al: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 138:958–968. 2010. View Article : Google Scholar : PubMed/NCBI
52	Laurent C, Valet F, Planque N, et al: High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 71:666–674. 2011. View Article : Google Scholar : PubMed/NCBI
53	Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Shedden K, Taylor JM, et al: Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI
54	Tomida S, Takeuchi T, Shimada Y, et al: Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol. 27:2793–2799. 2009. View Article : Google Scholar : PubMed/NCBI
55	Okayama H, Kohno T, Ishii Y, et al: Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
56	Lee ES, Son DS, Kim SH, et al: Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res. 14:7397–7404. 2008. View Article : Google Scholar : PubMed/NCBI
57	Yoshihara K, Tajima A, Yahata T, et al: Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One. 5:e96152010. View Article : Google Scholar : PubMed/NCBI
58	Gobble RM, Qin LX, Brill ER, et al: Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res. 71:2697–2705. 2011. View Article : Google Scholar : PubMed/NCBI